Explore every episode of the podcast Research Renaissance: Exploring the Future of Brain Science

Mental health care often feels disconnected from the rest of medical science. Dr. Greg Witkop, senior advisor for mental health at Renaissance Philanthropy, argues that it is time to treat the brain like any other organ. This conversation explores how we can bridge the gap between neuroscience and psychiatry to create more effective, data driven treatments that move us beyond simple symptom labels.

Key Takeaways
Mental health is brain health, and treating it with the same biological rigor as cardiology or oncology is essential.
Current diagnostic labels often act as an epistemic prison that limits our ability to treat the underlying physiological causes of suffering.
A precision psychiatry approach requires a biopsychosocial model that considers biology, social support, and environment equally.
We are currently at an inflection point where imaging, modeling, and interventional tools allow us to treat mental health with real measurable outcomes.

Main Points

Dr. Witkop shares his unique career journey, moving from ophthalmology and the FBI to DARPA, and why he now focuses on bringing rigor to mental health research. They discuss the historical silos between psychiatry and neuroscience, and why these divisions persist despite the fact that the brain constructs our entire subjective experience. The conversation also highlights the urgent need for a new ecosystem of care that mirrors models like St. Jude's or cancer research centers, focusing on shared protocols and patient outcomes rather than just stabilization.


Resources
Renaissance Philanthropy
National Institute of Mental Health (NIMH)
The Precision Psychiatry Roadmap (Molecular Psychiatry, 2025)
Now Matters Now organization

If you found this discussion valuable, please subscribe to the show on your favorite podcast platform and share this episode with a colleague or friend. Your support helps us reach more listeners interested in the future of health science.

To learn more about the breakthroughs discussed in this episode and to support ongoing research, visit our website at tofflertrust.org.

Technical Podcast Support by Jon Keur at Wayfare Recording Co.

Addiction treatment has historically relied on self-reporting and intermittent check-ins. Rachel Hobert, CEO of Huml Health, joins the show to discuss how her company is using wearable technology and voice biomarkers to provide clinicians with a clearer, continuous picture of a patient's health. We discuss the role of data in predicting struggles, the importance of the mind-body connection, and the challenges of innovating within a slow-to-adopt healthcare industry.

Key Takeaways

• The Shift to Passive Monitoring: Addiction treatment is moving from relying solely on patient self-reports to using objective biometric data like heart rate variability and sleep patterns to understand how a patient is truly doing.
• A Tool for Clinicians: Huml Health acts as a clinical decision support tool rather than a diagnostic device, surfacing engagement signals that help doctors ask the right questions at the right time.
• Connection is Key: The opposite of addiction is connection. Technology can facilitate that connection by keeping families and clinicians informed and engaged throughout the recovery journey.
• Overcoming Industry Hurdles: Healthcare innovation faces significant barriers, including slow adoption and misaligned incentives. Success requires a clear purpose and persistence.

Resources Mentioned
Huml Health
Canary Speech
Dr. Scott Lucas (Harvard McLean Medical School)

If you found this episode helpful, please subscribe to the show on your favorite platform and share it with someone who might benefit from this conversation. Your support helps us bring more of these vital stories to light.

To learn more about the breakthroughs discussed in this episode and to support ongoing research, visit our website at tofflertrust.org.

Technical Podcast Support by Jon Keur at Wayfare Recording Co.

How are deep ocean dynamics, extreme weather, and human health intertwined? In this episode of Research Renaissance, host Deborah Westphal sits down with Dr. Joellen Russell-a leading oceanographer and professor at the University of Arizona-to explore how the world’s oceans act as the ultimate life-support system for our planet.

From her childhood north of the Arctic Circle to surviving 50-foot waves in the Southern Ocean, Dr. Russell shares her journey of uncovering how deep sea upwelling impacts global temperatures, local heat waves, and the biological limits of human resilience. Discover how grassroots action, autonomous float technology, and cross-disciplinary research between neuroscientists and climate scientists are shaping the future of global adaptation.

Key Takeaways

• The Southern Ocean Bellows: The Antarctic Circumpolar Current is the largest on Earth, pulling ancient, nutrient-rich deep water to the surface and regulating global heat absorption.
• Human & Neurological Resilience: Rising heat waves directly impact cognitive health, vulnerable populations (elders and infants), and daily community routines.
• Technological Evolution: Autonomous Argo floats with biogeochemical sensors have transformed weather, ocean, and fish forecasting globally.
• Grassroots Solutions: Communities, farmers, and everyday people are driving energy transitions locally to lower costs and increase resilience regardless of national policy debates.
• The Talent Gap: With only ~6,000 PhD-level research oceanographers worldwide, there is an urgent need for more researchers across every discipline.

Guest Info & Mentioned Resources

Guest: Dr. Joellen Russell, Professor of Geosciences and Planetary Sciences at the University of Arizona.
Guest Contact: Reach Dr. Russell directly via the University of Arizona Faculty Page.

Resources Mentioned:

Karen Toffler Charitable Trust
Science Moms
Argo Global Ocean Observing Array

If you enjoyed this episode, please subscribe to Research Renaissance on Apple Podcasts, Spotify, or your favorite platform, and share this episode with a friend or colleague to help spread the word about groundbreaking science!

To learn more about the breakthroughs discussed in this episode and to support ongoing research, visit our website at tofflertrust.org.

Technical Podcast Support by Jon Keur at Wayfare Recording Co.

In this episode of Research Renaissance, host Deborah Westphall sits down with Dr. Wolfgang Stein, a professor at Illinois State University School of Biological Sciences. Dr. Stein shares his fascinating journey into neurobiology, how studying simple neural circuits in animals helps us understand complex brain function, and why flexibility is actually the foundation of biological robustness.

Key Takeaways

• Discover how a chance encounter with neurophysiology during an undergraduate course changed Dr. Stein's career path.
• Learn why studying small neural circuits provides crucial insights into how nervous systems generate and control behavior.
• Explore the connection between environmental changes, temperature extremes, and neural adaptability.
• Understand the balance between flexibility and robustness in biological systems and what it means for health science.

Main Discussion Points

• From Genetics to Neurobiology: Dr. Stein discusses his early pivot from genetics to recording neurons in leeches and the inspiring research environment at the University of Pennsylvania.
• The Roadmap Analogy: Why brain connectivity maps are necessary but not sufficient to understand neural output without knowing the underlying neuromodulation and activity.
• Environmental Stress and Temperature: How sudden temperature shifts and heatwaves impact nervous systems across species and why researchers are studying these effects.
• Embracing Failure in Science: Why curiosity and resilience in the face of unexpected results are essential traits for every researcher.

Resources and Mentions
Karen Toffler Charitable Trust
Illinois State University School of Biological Sciences
University of Pennsylvania
Kavli Foundation

If you enjoyed this episode, please subscribe, leave a review, and share it with friends and colleagues who are curious about the future of health science!

To learn more about the breakthroughs discussed in this episode and to support ongoing research, visit our website at tofflertrust.org.

Technical Podcast Support by Jon Keur at Wayfare Recording Co.

What if the blood vessels in your brain aren't just collateral damage in Alzheimer's disease, but part of the cause?

Dr. Rachel Bennett, associate professor at Massachusetts General Hospital and Harvard Medical School, is challenging one of the field's longest-held assumptions. In this episode, she joins host Deborah Westfall to break down her groundbreaking research on the relationship between tau pathology and vascular dysfunction, and why the future of Alzheimer's science may look nothing like what we expect today.

What You'll Learn in This Episode

• Why vascular changes in Alzheimer's disease were historically treated as secondary damage, and why that thinking is shifting
• How Dr. Bennett's lab discovered that tau pathology alone can drive abnormal changes in blood vessel structure
• The thick-tissue imaging technique that revealed something thin slides had been missing for decades
• What 47 meters of blood vessels in a single brain fold tells us about the scale of this problem
• Why the field may be drastically underestimating the number of distinct Alzheimer's disease subtypes
• How AI and spatial transcriptomics are accelerating discoveries that would have taken years under traditional funding timelines
• The critical role of philanthropic funding for early-career researchers, and why smaller, faster grants can outperform traditional NIH timelines

About Dr. Rachel Bennett

Dr. Rachel Bennett is an associate professor at Massachusetts General Hospital and Harvard Medical School, and a 2024 and 2025 Toffler Scholar. She runs the Bennett Alz Lab, which focuses on vascular contributions to Alzheimer's disease using cutting-edge imaging techniques including light sheet microscopy, in vivo two-photon microscopy, and spatial transcriptomics. She completed her PhD at Washington University in St. Louis studying traumatic brain injury and microglia, and her postdoctoral training in the lab of Dr. Bradley Hyman at MGH.

Resources and Links

• Bennett Alz Lab: bennettallzlab.com
• Connect with Dr. Bennett on LinkedIn
• Karen Toffler Charitable Trust: karrentoffler.org
• Massachusetts Alzheimer's Disease Research Center (Massachusetts ADRC)
• Research referenced: Acta Neuropathologica (tau and vascular accumulation study)

If this episode opened your eyes to a new side of Alzheimer's research, please leave a review on Apple Podcasts or Spotify. Share it with someone who cares about brain health, and subscribe so you never miss an episode of Research Renaissance.

To learn more about the breakthroughs discussed in this episode and to support ongoing research, visit our website at tofflertrust.org.

Technical Podcast Support by Jon Keur at Wayfare Recording Co.

What if the roots of anxiety, depression, and early puberty trace back to the first years of life — and we've been asking the wrong questions?

In this episode, host Deborah Westphal sits down with Angarika Balakrishnan, PhD candidate at the Brenhouse Lab at Northeastern University, whose research links early-life adversity to long-term brain development, neuroendocrine disruption, and mental health outcomes.

Key Takeaways

• Early-life adversity is not a single variable — timing, type, and predictability each produce different biological signatures in the developing brain
• The CRHR1 receptor in the hypothalamus may be a targetable mechanism for preventing early-onset puberty and adolescent anxiety
• Exercise during adolescence could serve as a treatment paradigm for metabolic, immune, and cognitive outcomes linked to early stress
• Depression, anxiety, and PTSD share underlying circuitry — treating them as separate conditions has slowed progress
• Science rewards certainty over doubt, and that culture is driving a mental health crisis inside PhD programs

About Angarika
PhD candidate, Brenhouse Lab, Northeastern University. Recently published in Hormones and Behavior and Neurobiology of Stress. Research supported by the Karen Toffler Charitable Trust.

Enjoyed this episode? Subscribe, leave a review, and share with anyone passionate about brain science or mental health.

To learn more about the breakthroughs discussed in this episode and to support ongoing research, visit our website at tofflertrust.org.

Technical Podcast Support by Jon Keur at Wayfare Recording Co.

What if diagnosing PTSD, anxiety, and depression could be as objective as a blood test — done in 10 minutes on your phone?

That's the vision behind Sensei, a company using AI and ocular biometrics to bring measurable, objective diagnostics to mental health. In this episode, host Deborah Westphal sits down with David Zakariaie, founder and CEO of Sensei, to talk about the science of the eye, a $2M technology problem solved with a commercial camera, and why fixing mental health starts with fixing measurement.

Key Takeaways

• Mental health's biggest crisis isn't just a shortage of care — it's a measurement problem. Major depression, the most commonly diagnosed mental health condition in the U.S., is misdiagnosed approximately 65% of the time. PTSD, bipolar, and schizophrenia are misdiagnosed between 84–92% of the time.
• Sensei's diagnostic app shows patients a series of ocular stimuli for roughly 10.5 minutes, captures their eyes' responses via a standard smartphone camera, and outputs a binary diagnosis plus a severity score.
• The platform measures approximately 45 individual metrics across three categories: traditional ocular metrics (pupil size, blinks, saccades, gaze), iris dilator and sphincter dynamics (mapping sympathetic vs. parasympathetic nervous system activity), and heart rate and heart rate variability from facial video.
• Sensei is currently in Phase 3 clinical trials for a PTSD diagnostic, with an FDA submission planned for late 2025 and approval expected in 2027.
• About 16,000 people participated in pre-trial studies; the full dataset at submission is expected to reach approximately 30,000.
• The go-to-market strategy focuses on telehealth platform integration — partnering with companies like Spring Health, Talkspace, and BetterHelp to embed the diagnostic tool directly into existing care delivery workflows.
• Future expansion targets schizophrenia, bipolar disorder, and ADHD, with longer-term interest in neurodegenerative conditions like Alzheimer's and dementia.

About David Zacharia

David Zakariaie is the founder and CEO of Sensei, a mental health diagnostics company building the first FDA-regulatory-grade platform for diagnosing and monitoring PTSD, anxiety, and depression using AI-powered ocular biometrics. His path began at 15, when he attended Google I/O, received an early pair of Google Glass, and became fascinated with the scientific potential of the human eye. He left high school after 10th grade, taught himself to code, and launched the company in 2015.

Resources & Links Mentioned

• Sensei: sensei.health (verify current URL)
• Mental Health Study (Phase 3 Trial Sign-Up): mentalhealthstudy.org
• Karen Toffler Charitable Trust: tofflertrust.org (verify current URL)
• Parea Therapeutics (digital therapeutics reference)
• The CAPS-5 (Clinician-Administered PTSD Scale)
• The PCL-5 (PTSD Checklist for DSM-5)

If You Enjoyed This Episode

Subscribe to Research Renaissance wherever you listen to podcasts. If this conversation sparked something for you, share it with someone in healthcare, mental health advocacy, or neuroscience — this is the kind of work that needs more eyeballs on it.

To learn more about the breakthroughs discussed in this episode and to support ongoing research, visit our website at tofflertrust.org.

Technical Podcast Support by Jon Keur at Wayfare Recording Co.

Are you trading your long-term brain health for late-night screen time? Dr. Paul Chung, physician and researcher at Northwestern University, joins host Deborah Westphal to reveal why sleep is far more than rest - and why ignoring it could cost you decades of cognitive health.

Dr. Chung is an Assistant Professor at Northwestern University, a pulmonary and sleep medicine physician, and a 2023 Toffler Scholar. His research sits at the intersection of sleep, circadian biology, and Alzheimer's disease - with a special focus on adults with Down syndrome as a model for understanding cognitive decline.

What You'll Learn in This Episode

• Why sleep is an active process of repair - not passive rest - and how it regulates your heart, brain, immune system, and metabolism
• What sleep apnea actually is (beyond snoring) and why it causes a body-wide stress response every single night
• Why sleep apnea remains dramatically underdiagnosed - even 60 years after being formally defined - and what patients say when asked why they skip sleep studies
• The shocking truth: a third of adults and children still aren't getting enough sleep, and the number is even worse for teenagers
• How disrupted circadian rhythms are linked to the buildup of amyloid beta - the protein central to Alzheimer's disease
• Why individuals with Down syndrome are an invaluable research population for understanding Alzheimer's progression in the broader population
• What "slow wave activity" in sleep EEG data reveals about cognitive decline
• The science of chronotherapy - why when you take a medication or vaccine may be just as important as what you take
• Night owls vs. early birds: the genetic reality behind your body clock, and why society quietly punishes night owls
• The future of personalized sleep medicine - beyond CPAP

Key Takeaway
Sleep is the third pillar of health alongside diet and exercise - yet it's the one most people sacrifice first

About Dr. Paul Chung
Dr. Paul Chung is a physician and Assistant Professor at Northwestern University's Feinberg School of Medicine, specializing in pulmonary and sleep medicine. He is a 2023 Toffler Scholar whose research focuses on sleep EEG microstructure, actigraphy, and circadian rhythms as they relate to cognitive vulnerability and Alzheimer's disease - with a particular emphasis on adults with Down syndrome.

Research inquiries: paul.chung@northwestern.edu (For clinical appointments, contact Northwestern Medicine directly.)

Resources Mentioned
Karen Toffler Charitable Trust - Funding innovative, early-stage health research: tofflertrust.org
NIH INCLUDE Project - Initiative to increase Down syndrome research funding: www.nih.gov
Alzheimer's Biomarkers Consortium for Down Syndrome (ABC-DS) - Large collaborative cohort study
Northwestern University Feinberg School of Medicine - Sleep Medicine Program

If this conversation opened your eyes to the power of sleep science, please subscribe, leave a review, and share it with someone who keeps saying they'll "sleep when they're dead." Your support helps us bring more groundbreaking researchers to this mic.

To learn more about the breakthroughs discussed in this episode and to support ongoing research, visit our website at tofflertrust.org.

Technical Podcast Support by Jon Keur at Wayfare Recording Co.

What if the key to understanding autism isn't one gene — but thousands working together?

In this episode of Research Renaissance, host Deborah Westphal sits down with Dr. Daniel Gershwind, Gordon and Virginia McDonald Distinguished Professor of Human Genetics, Neurology, and Psychiatry at UCLA, and Associate Vice Chancellor for Precision Health. A true pioneer in neurogenomics, Dr. Gershwind has spent over two decades reshaping how we understand autism and complex brain disorders — from building one of the first autism gene banks to applying transcriptomic network methods that revealed the molecular landscape of the brain in entirely new ways.

This conversation is as much about the science as it is about how science gets done — through collaboration, curiosity, and a willingness to tackle the problems others walk away from.

Key Takeaways

• Genetics doesn't mean "everything is genetic" — all human disease has both genetic and environmental components, but genetics offers a powerful, tractable starting point for understanding cause
• Looking at gene networks (rather than single genes) transformed the field by making sense of hundreds or thousands of genes at once — and revealing how biological systems adapt and respond to disruption
• Autism affects approximately 1 in 100 children today — not because rates have risen, but because our ability to diagnose it has dramatically improved over the past 30 years
• About 15% of people with autism can now be identified with a specific causative genetic mutation through whole genome or exome sequencing — pointing toward targeted, precision therapies
• Transcriptomics (measuring RNA expression across the brain) revealed shared molecular patterns in autism brains across different patients — a surprising convergence that has since been validated in large sample sizes
• Autism, schizophrenia, and bipolar disorder share some molecular pathology but are mostly molecularly distinct — a finding only visible at the transcriptomic level
• CRISPR activation (without genome editing) has already been used in lab models to restore normal neuronal firing in certain autism-linked epilepsy syndromes — a proof of concept for future therapies
• AI is now being used to connect gene networks to existing drugs, potentially accelerating drug discovery without needing full mechanistic understanding
• Neurodegeneration (including Alzheimer's and frontotemporal dementia) is closer to clinical trials than autism — but the two fields are informing each other in real time

About the Guest

Dr. Daniel Gershwind is the Gordon and Virginia McDonald Distinguished Professor of Human Genetics, Neurology, and Psychiatry at UCLA. He leads the Gershwind Lab and serves as Associate Vice Chancellor for Precision Health. He co-founded the Autism Genetic Resource Exchange (AGRE), which became the leading data resource for autism genetics research for over a decade, and has been instrumental in developing transcriptomic network approaches now used widely across the field.

Resources & Links

• Karen Toffler Charitable Trust: karentoffler.org
• Autism Genetic Resource Exchange (AGRE)
• UCLA Gershwind Lab
• PsychENCODE Consortium

Enjoyed this episode? Subscribe to Research Renaissance wherever you listen to podcasts, leave us a review on Apple Podcasts, and share this episode with anyone who cares about the future of brain health research. Every share helps bring this science to more people.

To learn more about the breakthroughs discussed in this episode and to support ongoing research, visit our website at tofflertrust.org.

Technical Podcast Support by Jon Keur at Wayfare Recording Co.

What if one of the most promising frontiers in Alzheimer's research isn't just about what's building up in the brain - but how the brain clears it out? In this episode of Research Renaissance, host Deborah Westphal sits down with Dr. Tirth Patel, a neurologist and physician-scientist at UCLA and 2025 Toffler Scholar, to explore the cutting-edge science of brain clearance, tau protein, and the newly discovered lymphatic vessels surrounding the brain.

This is a conversation about curiosity, persistence, and the kind of early-career science that could reshape how we understand and treat dementia.

What You'll Learn in This Episode

• What tau protein is, why it "gunks up" the brain, and how it differs from amyloid beta in Alzheimer's disease
• The recently discovered lymphatic vessels in the brain's meninges - and why they matter for clearing toxic proteins
• How sleep deprivation spikes tau and amyloid levels in the blood, and what that means for long-term brain health
• The glymphatic system: the brain's internal waste-clearance highway and its deep connection to sleep
• Why aging slows down the brain's lymphatic drainage - and what researchers are doing about it
• The genetics of Alzheimer's: the difference between causative mutations (APP, PS1, PS2) and risk factors like APOE4
• New FDA-approved blood tests and the promise of tau PET scans for better diagnosis and staging
• The latest treatments for Alzheimer's - how they work, their limitations, and what's coming next
• Why failure is one of the most undervalued tools in science - and what's missing in how the field handles negative data
• A candid take on AI in biological research: where it helps, where it falls short, and whether it lets scientists fail

About Our Guest

Dr. Tirth Patel is a neurologist and physician-scientist at UCLA, currently working in the lab of Dr. Jason Hinman. His research focuses on how the brain's meningeal lymphatic vessels clear tau protein from the brain to the bloodstream - a question with major implications for Alzheimer's disease and related dementias. Dr. Patel is a 2025 Toffler Scholar, supported by the Karen Toffler Charitable Trust. He is also the co-host of the podcast Recreational Science, where he and his colleague Dr. Lou Yang explore wacky but well-designed scientific studies to illuminate the scientific method.

📧 Reach Dr. Patel: tkpatel@mednet.ucla.edu

Resources & Links Mentioned

• Karen Toffler Charitable Trust
• Recreational Science Podcast - co-hosted by Dr. Tirth Patel and Dr. Lou Yang
• UCLA Department of Neurology
• Alzheimer's Association resources on APOE4, tau, and amyloid

Like what you heard? Subscribe to Research Renaissance on Apple Podcasts, Spotify, or wherever you listen. Leave us a review - it helps more people discover the science that matters. And share this episode with someone who cares about brain health, aging, or the future of medicine.

Research Renaissance is presented by the Karen Toffler Charitable Trust.

To learn more about the breakthroughs discussed in this episode and to support ongoing research, visit our website at tofflertrust.org.

Technical Podcast Support by Jon Keur at Wayfare Recording Co.

The Hidden Genome Inside Every Cell

Most of us learned that mitochondria are the “powerhouse of the cell.”
What we didn’t learn?

They carry their own DNA — and that DNA may hold crucial answers to aging, neurodegeneration, and rare childhood diseases.

In this episode of Research Renaissance, host Deborah Westphal speaks with Dr. Stefan Isaac, Assistant Professor at Boston University and 2025 Toffler Scholar, about how mitochondrial DNA is organized, regulated, and why its dysfunction may contribute to diseases ranging from Leigh syndrome to Alzheimer’s.

🎯 Key Takeaways

• Every cell contains hundreds to thousands of copies of mitochondrial DNA
• Mitochondrial mutations accumulate over time and may drive aging and disease
• There is a biochemical threshold — disease often appears when 60–80% of mitochondrial genomes are mutated
• New long-read sequencing technologies allow researchers to study mitochondrial DNA at single-molecule resolution
• Emerging therapies aim to tip the balance toward healthy mitochondrial genomes
• Mitochondrial dysfunction plays a role in:
• Rare primary mitochondrial diseases
• Neurodegenerative diseases (Alzheimer’s, Parkinson’s)
• Neuromuscular and metabolic disorders

🧪 Featured Topics

• Mitochondrial gene expression
• DNA accessibility and genome packaging
• Induced pluripotent stem cells (iPSCs)
• Cortical neuron models
• Mutation drift vs. selective replication
• Environmental exposure and mitochondrial health
• Antibiotic-associated mitochondrial toxicity

🔬 About Our Guest
Dr. Stefan Isaac
Assistant Professor, Boston University
Research focus: Mitochondrial genome regulation, replication, and dysfunction in aging and disease.

If you found this conversation insightful:

• Follow Research Renaissance
• Share this episode with a colleague
• Leave a review on Apple Podcasts or Spotify
• Send it to someone interested in neuroscience, aging, or rare diseases

The future of medicine begins with understanding the cell.

To learn more about the breakthroughs discussed in this episode and to support ongoing research, visit our website at tofflertrust.org.

Technical Podcast Support by Jon Keur at Wayfare Recording Co.

What if the next breakthrough in mental health didn’t start in a lab — but in nature?

In this episode of Research Renaissance, host Deborah Westphal speaks with Dr. Jacob Hooker, neuroscientist, entrepreneur, and CEO of Sensorium Therapeutics. Dr. Hooker shares how his journey from textile chemistry to molecular imaging led him to build a biotech company focused on nature-inspired treatments for anxiety and other neurological conditions.

With nearly 20% of the U.S. population diagnosed with an anxiety disorder, the need for better treatments is urgent. Dr. Hooker explains why current psychiatric care often relies on trial-and-error prescribing — and how brain imaging, biomarkers, and computational tools may help match patients to the right treatment faster.

This conversation explores the intersection of neuroscience, genetics, psychedelics, stigma, and precision medicine — and why solving even one patient’s journey can create ripple effects for millions.

🔑 Key Takeaways

• Why 85% of brain medicines originate from observations in nature
• The science behind anxiety — and why it’s more than “just feelings”
• How EEG and imaging biomarkers could reduce trial-and-error prescribing
• The resurgence of psychedelic research — and what it’s teaching us
• Why unpredictability in modern life may be driving anxiety rates
• The founder journey from academia to biotech entrepreneurship

⏱️ Episode Timestamps
00:00 – Welcome to Research Renaissance
01:00 – From textile chemistry to neuroscience
03:00 – Why anxiety became Sensorium’s first focus
05:00 – Nature as the origin of psychiatric medicines
10:00 – Psychedelics, drug development, and new mechanisms
13:00 – Social anxiety disorder and stigma
21:00 – Brain imaging and biomarker-guided treatment
27:00 – Why stopping medication can restart the cycle
29:00 – Is modern life increasing anxiety?
33:00 – Personal journey: growing up with mental illness
42:00 – Defining impact in mental health

👤 Guest

Dr. Jacob Hooker
 Neuroscientist, entrepreneur, and CEO of Sensorium Therapeutics
 Founder of Ether in Mind (Substack)

🔬 About Sensorium Therapeutics

Sensorium Therapeutics develops nature-inspired treatments for anxiety and related neurological conditions. Their approach integrates computational chemistry, molecular imaging, and biomarker strategies to personalize psychiatric treatment.

💬 Join the Conversation

If this episode expanded your understanding of mental health science:

• Follow Research Renaissance
• Share this episode with a colleague or friend
• Leave a review on Apple Podcasts or Spotify
• Visit the Karen Toffler Charitable Trust to explore more conversations

To learn more about the breakthroughs discussed in this episode and to support ongoing research, visit our website at tofflertrust.org.

Technical Podcast Support by Jon Keur at Wayfare Recording Co.

What if depression and anxiety are not just disorders of the brain, but conditions shaped by the entire body?

In this episode of Research Renaissance, host Deborah Westphal speaks with Dr. Scott Russo, Director of the Brain Body Research Institute at Mount Sinai, about a major shift underway in mental health science. His work challenges the long-standing brain-only model of psychiatric illness and explores how inflammation, immune signaling, and organ systems interact with the brain to shape mood, resilience, and disease risk.

From gut health to traumatic injury, this conversation reveals why mental health research is moving toward an integrative “systems biology” approach that could redefine treatment in the next decade.

Key Takeaways

• Mental illnesses often coexist with medical conditions, suggesting they are whole-body disorders rather than isolated brain diseases.
• Chronic inflammation may be a shared biological driver across conditions ranging from depression to cardiovascular disease.
• Signals from peripheral organs can influence emotional states, meaning some emotions may originate in the body before being processed by the brain.
• Environmental exposures, infections, and life experiences may account for the majority of mental health risk, with genetics contributing a smaller portion.
• Emerging therapies may target immune pathways or body-brain signaling rather than neurotransmitters alone.
• Collaboration across disciplines is essential to advancing mental health research, yet institutional silos still limit innovation.

About the Guest

Dr. Scott Russo is Director of the Brain Body Research Institute at the Icahn School of Medicine at Mount Sinai. His work focuses on understanding how immune, metabolic, and neural systems interact to influence psychiatric disorders and resilience.

Resources & Mentions

• Brain-Body Research Institute at Mount Sinai
• Research on inflammation and psychiatric disease
• Advances in vagus nerve stimulation therapies

If you enjoyed this episode:

• Follow Research Renaissance for more conversations shaping the future of health science.
  
  
  
• Share this episode with a colleague exploring neuroscience, psychiatry, or integrative medicine.
  
  
  

Leave a review to help others discover the show.

To learn more about the breakthroughs discussed in this episode and to support ongoing research, visit our website at tofflertrust.org.

Technical Podcast Support by Jon Keur at Wayfare Recording Co.

Modern medicine is not shaped by science alone. It is shaped by ethics, trust, and the difficult decisions made when technology moves faster than society can understand it.

In this episode of Research Renaissance, legendary bioethicist Dr. Art Caplan reflects on a career that helped build the field of bioethics from the ground up. From surviving polio as a child to shaping national policies on organ transplantation, informed consent, and end-of-life care, Caplan offers a deeply personal and historically grounded perspective on how ethical thinking became essential to modern healthcare.

The conversation explores the lingering distrust born from COVID-19, the ethical blind spots of artificial intelligence, the environmental cost of data infrastructure, and why communication between science and the public may be the most urgent challenge ahead.

This episode is both a history lesson and a call to action. Ethics is not abstract philosophy. It is practical problem-solving for real people, real patients, and real consequences.

Key Takeaways

• Bioethics emerged to solve real clinical dilemmas, not theoretical debates.
• Policies such as informed consent, brain-death standards, and organ allocation were shaped by early bioethics work.
• Public trust in medicine declined significantly after COVID-19 due to shifting scientific guidance and poor communication.
• AI introduces ethical risks beyond autonomy and bias, including environmental strain, privacy vulnerability, and unclear liability.
• The U.S. healthcare system’s structure, not just its technology, drives many ethical failures.
• Ethics must move from academic journals into communities through direct engagement and public dialogue.
    

Guest Spotlight

Art Caplan, PhD
One of the founders of modern bioethics, Dr. Caplan has advised governments, medical institutions, and research bodies on issues ranging from organ transplantation policy to emerging AI ethics. His work bridges philosophy, clinical medicine, and public engagement.

Topics Discussed

• Origins of bioethics as a discipline
• Human subject protections and informed consent
• End-of-life decision frameworks and hospice care
• Vaccine hesitancy and post-pandemic mistrust
• Ethical governance of artificial intelligence in healthcare
• Environmental implications of digital infrastructure
• Structural inequities in U.S. healthcare delivery
• The role of communication in rebuilding scientific trust

If you found this conversation valuable:

• Follow Research Renaissance for more conversations at the intersection of science, policy, and human health.
• Share this episode with colleagues working in healthcare, research, or ethics.
• Leave a review to help more listeners engage with these critical discussions.

To learn more about the breakthroughs discussed in this episode and to support ongoing research, visit our website at tofflertrust.org.

Technical Podcast Support by Jon Keur at Wayfare Recording Co.

Parkinson’s disease begins decades before symptoms appear — and by the time tremors start, brain changes have already been unfolding for years.
In this episode of Research Renaissance, host Deborah Westphal speaks with Dr. 

Zachary Sorrentino, neurosurgeon, physician-scientist, and 2025 Toffler Scholar at the University of Florida. Dr. Sorrentino explains how misfolded proteins like alpha-synuclein spread through the brain, how deep brain stimulation helps restore movement, and why preventing dementia in Parkinson’s patients may be the next major frontier.

Drawing from both the operating room and the research lab, Dr. Sorrentino shares how his team analyzes proteins directly from surgical tools used in living patients — offering unprecedented insight into disease progression.
This is a powerful conversation about aging, brain vulnerability, precision therapies, and the human side of neurosurgery.

🔑 Key Takeaways
Why age is the strongest risk factor for Parkinson’s disease
How misfolded alpha-synuclein spreads through the brain
What deep brain stimulation actually does
Why Parkinson’s symptoms begin decades before diagnosis
The connection between Parkinson’s and dementia
How targeted drug delivery through brain blood vessels may shape the future
The emotional realities of neurosurgery and patient care

⏱️ Episode Timestamps
00:00 – Introduction to Parkinson’s and Lewy body disorders
02:30 – The MD-PhD pathway and physician-scientist model
08:30 – What deep brain stimulation does
10:00 – The 20-year silent phase of Parkinson’s
12:00 – Studying proteins from surgical tools
16:00 – Why dementia is the greatest fear
24:00 – How misfolded proteins spread
27:00 – The role of aging in neurodegeneration
31:00 – Detecting pathological proteins in living patients
42:00 – Stroke breakthroughs in the last decade
48:00 – Targeted therapies and personalized brain medicine
54:00 – The human side of neurosurgery

👤 Guest
Dr. Zachary Sorrentino
Neurosurgeon and Physician-Scientist
University of Florida
2025 Toffler Scholar

🧠 Topics Covered

• Parkinson’s disease
• Alpha-synuclein and Lewy bodies
• Protein misfolding and neurodegeneration
• Deep brain stimulation (DBS)
• Targeted gene therapy delivery
• Stroke intervention advances
• Aging and brain health

💬 Join the Conversation
If this episode deepened your understanding of Parkinson’s disease:
Follow Research Renaissance
Share this episode with someone in neuroscience or medicine
Leave a review on Apple Podcasts or Spotify
Subscribe for more conversations shaping the future of human health

To learn more about the breakthroughs discussed in this episode and to support ongoing research, visit our website at tofflertrust.org.

Technical Podcast Support by Jon Keur at Wayfare Recording Co.

For decades, Parkinson’s disease has been viewed primarily as a disorder of dopamine-producing brain cells.

But what if that’s only part of the story?

In this episode of Research Renaissance, host Deborah Westphal sits down with Dr. Rebecca Wallings, Assistant Professor of Neurology at Indiana University’s Stark Neuroscience Research Institute, to explore a groundbreaking shift in how we understand Parkinson’s.

Dr. Wallings explains why the immune system — and specifically immune cell exhaustion — may be a key driver of disease progression. She challenges the prevailing “too much inflammation” narrative and introduces the provocative idea that Parkinson’s may involve a burned-out, aging immune system rather than simply an overactive one.

This conversation dives into:

• The role of lysosomes in immune and brain cells
  
  
• Why most preclinical Parkinson’s models may overlook aging
  
  
• Gut-first vs. brain-first Parkinson’s subtypes
  
  
• Immune exhaustion and its connection to aging
  
  
• Lifestyle factors that may influence disease progression
  
  
• Why future therapies may need to be personalized
  
  

Key Takeaways

• Parkinson’s may be a whole-body condition, not just a brain disease.
  
  
• Aging dramatically alters immune function — yet many models study “young” immune systems.
  
  
• Immune exhaustion may prevent proper resolution of inflammation.
  
  
• Non-motor symptoms (constipation, sleep disorders, loss of smell) can appear decades before diagnosis.
  
  
• Stratifying patients by biological immune age could transform treatment strategies.

 About Our Guest

Dr. Rebecca Wallings
Assistant Professor of Neurology
Indiana University – Stark Neuroscience Research Institute

Dr. Wallings studies the role of immune cell exhaustion and aging in Parkinson’s disease, challenging traditional pathology-focused models and exploring translational therapeutic strategies.

Resources Mentioned

• Stark Neuroscience Research Institute
• Research on immune checkpoint inhibitors
• Studies on REM Behavior Disorder and Parkinson’s risk
• Research into biological aging clocks

Enjoyed This Episode?

If this conversation expanded your thinking:

• Subscribe to Research Renaissance
• Leave a review on Apple Podcasts or Spotify
• Share this episode with a colleague or friend
• Follow us for more conversations at the frontier of health science

To learn more about the breakthroughs discussed in this episode and to support ongoing research, visit our website at tofflertrust.org.

Technical Podcast Support by Jon Keur at Wayfare Recording Co.

In this episode of Research Renaissance, host Deborah Westphal sits down with neuroscientist Micaelly Alves, PhD candidate at Temple University and a 2025 Toffler Scholar supported by the Karen Toffler Charitable Trust.

Micaelly shares her personal journey into neuroscience, inspired by watching her grandmother’s battle with Alzheimer’s disease, and dives into groundbreaking research on microRNAs, tiny molecules that may hold the key to earlier diagnosis and more personalized treatment for Alzheimer’s and cerebral amyloid angiopathy.

The conversation explores how brain research is evolving, why personalized medicine matters, and how emerging technologies like RNA sequencing and bioinformatics are accelerating discovery.

⭐ Key Takeaways

• How microRNAs regulate brain pathways linked to Alzheimer’s disease
• Why Alzheimer’s may begin developing 20 years before symptoms appear
• The role of blood-brain barrier health in cognitive decline
• How extracellular vesicles may enable early blood-based diagnostics
• Why personalized medicine is the future of neurological care
• The challenges and promise of big data and AI in neuroscience
• How philanthropy supports early-career researchers and innovation

🔬 Resources & Mentions

• Temple University Neuroscience Program
• MicroRNA research in Alzheimer’s disease
• Cerebral amyloid angiopathy (CAA)
• RNA sequencing and transcriptomics

👉 Enjoying Research Renaissance?

If you found this episode helpful:

✅ Subscribe on Apple Podcasts or Spotify
✅ Share this episode with a friend or colleague
✅ Leave a review to help more listeners discover the show

To learn more about the breakthroughs discussed in this episode and to support ongoing research, visit our website at tofflertrust.org.

Technical Podcast Support by Jon Keur at Wayfare Recording Co.

How does neuroscience shape state policy? And what happens when scientists step inside government?

In this episode of Research Renaissance, Deborah Westphal sits down with Dr. Julianne McCall, CEO of the California Council on Science and Technology (CCST), to explore how scientific thinking informs public policy in one of the world’s largest economies.

From spinal cord injury research in Germany to advising California’s Governor during COVID-19, Dr. McCall shares how scientists can help governments navigate AI, climate, energy, and public health in a rapidly accelerating world.
This conversation reveals what it really takes to translate research into action.

Key Takeaways
Why scientific training is uniquely suited for policymaking
How California integrates nonpartisan science advisors into government
The role of “the Third House” in shaping legislation
Why AI policy must evolve every six months
How fellowship programs are training the next generation of science policy leaders
Why community and trust are central to effective governance

About the Guest
Dr. Julianne McCall
CEO, California Council on Science and Technology
Neuroscientist turned science policy leader with experience spanning academia, international research, state government, and public engagement.

Resources & Links
California Council on Science and Technology: https://ccst.us
CCST Science & Technology Policy Fellowship
Calls for Experts (AI, Quantum, Emerging Technologies)
Science & Technology Week at the California State Capitol

Listen & Connect
If you found this episode valuable:
Follow Research Renaissance
Share this episode with a colleague in science or public policy
Leave a review on Apple Podcasts or Spotify
Science doesn’t move society alone. It needs translation.

To learn more about the breakthroughs discussed in this episode and to support ongoing research, visit our website at tofflertrust.org.

Technical Podcast Support by Jon Keur at Wayfare Recording Co.

In this episode of Research Renaissance, host Deborah Westphal sits down with Dr. Şiyar Bahadır, neurosurgeon and Elmezzi Scholar at the Feinstein Institute for Medical Research, to explore the cutting edge of neuroscience, bioelectronic medicine, and the powerful role of the vagus nerve in regulating nearly every organ system in the body.

Dr. Bahadır shares his journey from the operating room to advanced research, explains how mapping the brain and nervous system is revolutionizing patient outcomes, and dives into groundbreaking therapies using electrical stimulation to treat inflammatory diseases like rheumatoid arthritis.

The conversation also uncovers how the brain reorganizes itself after trauma, the future of precision neurosurgery, and why the vagus nerve may hold the key to an entirely new form of medicine.

Key Takeaways

• The vagus nerve acts as a central communication highway between the brain and major organs
• How bioelectronic medicine uses electrical stimulation instead of drugs to treat disease
• Real-world success of vagus nerve stimulation for rheumatoid arthritis (now FDA approved)
• Why mapping neural networks improves surgical precision and recovery
• The brain’s ability to reorganize itself (plasticity) after injury or surgery
• How AI and advanced imaging are shaping the future of neurosurgery

Guest Information

Dr. Şiyar Bahadır
Neurosurgeon | Elmezzi Scholar | Feinstein Institute for Medical Research

📧 Email: sbahadir@northwell.edu
🔗 LinkedIn: Şiyar Bahadır

Resources Mentioned

• The Great Nerve by Dr. Kevin Tracy (on the vagus nerve and bioelectronic medicine)

If you enjoyed this episode, please:

✅ Subscribe to Research Renaissance
✅ Leave a review on Apple Podcasts or Spotify
✅ Share this episode with colleagues interested in neuroscience and medical innovation

Your support helps us bring more groundbreaking research conversations to you!

To learn more about the breakthroughs discussed in this episode and to support ongoing research, visit our website at tofflertrust.org.

Technical Podcast Support by Jon Keur at Wayfare Recording Co.

Healthcare today runs on data, but few people understand how deeply information systems shape patient outcomes, clinician workflows, and long-term public health. In this episode of Research Renaissance, host Deborah Westphal sits down with Dr. Caterina (Cat) Lasome, a nationally recognized leader in health informatics and digital health transformation.

Drawing from 23 years as an Army nurse and decades working across the Department of Defense, VA, NIH, and federal health systems, Cat explains how informatics sits at the intersection of clinical care, technology, and human behavior. Together, they explore what happens when data flows well, where systems still fracture, and why learning healthcare systems may be the key to safer, more adaptive medicine.

Key Topics & Takeaways

• What health informatics actually is and why it affects every patient encounter
• How military healthcare prepares clinicians for complexity at scale
• Why continuity of care between DoD and VA systems matters for veterans
• The hidden role of data standards, interoperability, and governance
• Clinical practice guidelines and how they improve consistency without replacing judgment
• Burnout, documentation burden, and the promise of ambient clinical listening
• Why healthcare struggles to learn from errors, and what aviation gets right
• What a true “learning healthcare system” would require to function

About the Guest

Dr. Caterina (Cat) Lasome is a nationally recognized expert in health informatics, clinical systems, and digital health transformation. A retired Army nurse with 23 years of service, she has worked across the Department of Defense, Veterans Affairs, NIH, and HHS, and is the President & CEO at iON Informatics, LLC. To contact Dr. Lasome cat@ioninformatics.com. 

Resources Mentioned

• Department of Defense Health System
• Veterans Health Administration (VA)
• Agency for Healthcare Research and Quality (AHRQ)
• Joint Trauma Registry (JTR)
• Electronic Health Records (EHRs)
• Ambient clinical documentation technology

If you found this episode valuable:

• Subscribe to Research Renaissance on your favorite podcast platform
• Share this episode with colleagues working in healthcare, research, or policy
• Leave a review to help more listeners discover the show

To learn more about the breakthroughs discussed in this episode and to support ongoing research, visit our website at tofflertrust.org.

Technical Podcast Support by Jon Keur at Wayfare Recording Co.

For decades, Alzheimer’s disease was treated as an unavoidable consequence of aging. In this episode of Research Renaissance, Dr. Jessica Rexach explains why that framing is no longer true.

Drawing on 20 years at the intersection of clinical neurology, genetics, and experimental neuroscience, Dr. Rexach walks us through a profound shift in the field. Today, scientists can model human brain circuits, measure Alzheimer’s pathology through blood-based biomarkers, and study why some brains remain cognitively resilient even with disease pathology present.

The science, she argues, is ready. The real question is whether society will commit the resources needed to finish the job.

Key Takeaways

• Alzheimer’s research has moved from broad hypotheses to precise, testable mechanisms
• Blood-based biomarkers have transformed clinical trials and early detection
• Brain resilience, not just pathology, may hold the key to prevention
• COVID-era investments unintentionally accelerated dementia research tools
• The biggest risk now is not scientific failure, but loss of funding and momentum

Guest Information

Dr. Jessica Rexach
Assistant Professor, UCLA
2024 Toffler Scholar

📧 Email: jrexach@mednet.ucla.edu

Listen & Subscribe

If you found this episode valuable:

• Subscribe to Research Renaissance on Apple Podcasts or Spotify
• Share this episode with colleagues, caregivers, or anyone interested in brain science
• Leave a review to help others discover the show

To learn more about the breakthroughs discussed in this episode and to support ongoing research, visit our website at tofflertrust.org.

Technical Podcast Support by Jon Keur at Wayfare Recording Co.

In this powerful episode of Research Renaissance, Arushi Raina and John Chernesky from the Praxis Spinal Cord Institute pull back the curtain on what it really takes to innovate in spinal cord injury—and why the future of neurological care depends on integrating technology, science, and most importantly, lived experience.

Rather than treating individuals as patients or passive recipients of care, Praxis centers their entire innovation pipeline around those living with spinal cord injury (SCI), involving them from ideation through market launch. Arushi shares how shifting from product “for” to product “with” the SCI community has accelerated meaningful breakthroughs. John explains why he refuses the label “patient” and instead champions the term Plex – Persons with Lived Experience, a philosophy now driving clinical research, product development, and even investment strategies.

From cutting-edge neuromodulation to low-cost wound gels saving lives, this conversation explores how innovation scales not by solving one condition in isolation—but by designing for complexity, translating solutions across adjacent neurological and aging populations, and creating sustainable pathways to market.

Key highlights include:

♿ Why integrating lived experience from day one leads to better innovation—and better outcomes

🔄 How a “test bed” approach in SCI is accelerating breakthroughs for MS, stroke, Parkinson’s, aging and more

⚙️ The surprising power of simple, scalable technologies—like a gel applied at the first sign of a pressure sore

🧩 Why coachability in entrepreneurs may matter more than capital in medtech success

🧠 Neuromodulation reversing effects of paralysis—and improving autonomic functions like temperature, bowel, and bladder control

💬 How real-time, direct feedback from SCI users saved startups from costly mistakes

📈 Why Praxis built a fund model that generates investor returns and channels profits back into the charity

❤️ What it means to rethink innovation around dignity, identity, and human mobility—not just mobility of limbs

Most profound takeaway

“If technology can be used not only to make it acceptable, but to celebrate the different ways people walk and move through the world, that’s where innovation meets humanity.” — Arushi Raina

Resources & Links

🌐 Praxis Spinal Cord Institute: PracticeInstitute.org
 🔗 Connect with Arushi & John on LinkedIn
 📧 General contact: info@practiceinstitute.org
 💡 Learn more about the Karen Toffler Charitable Trust: tofflertrust.org

Connect with Research Renaissance

💌 Subscribe for more thought-provoking interviews
 🌐 Visit: tofflertrust.org
 📲 Follow us on LinkedIn

To learn more about the breakthroughs discussed in this episode and to support ongoing research, visit our website at tofflertrust.org.

Technical Podcast Support by Jon Keur at Wayfare Recording Co.

In this episode of Research Renaissance, host Deborah Westphal sits down with Dr. Wendy Ellis, Assistant Professor of Global Health at George Washington University and Founding Director of the Center for Community Resilience. Together, they explore how resilience science and systems-level thinking can drive lasting change for communities impacted by adversity.

Dr. Ellis shares her groundbreaking Pair of ACEs Framework, which connects adverse childhood experiences to adverse community environments, and discusses how this approach is helping policymakers, educators, and community leaders address root causes rather than symptoms. From innovative school-based partnerships in Portland to the development of an Opportunity Dashboard that measures both social and economic return on community investments, this conversation reveals how data, collaboration, and hope can transform entire neighborhoods.

Whether you're a researcher, policymaker, or community advocate, this episode will inspire you to think bigger about what it means to build truly resilient communities.

🎙 What you’ll learn in this episode:
 • Why resilience science must go beyond individuals and address systems.
 • The power of the Pair of ACEs Framework in reframing public health and policy.
 • How community-driven solutions have produced measurable results in education, healthcare, and economic stability.
 • Why connecting health data with economic outcomes can shift investment and policy decisions.
 • The role of hope, social cohesion, and collaboration in driving lasting change.

Subscribe to Research Renaissance and join us in exploring the science, policy, and community action shaping the future of brain health and resilience. Visit tofflertrust.org for resources and updates.

#ResilienceScience #PublicHealth #PairOfACEs #CommunityResilience #SystemsThinking #SocialImpact #AdverseChildhoodExperiences #HealthEquity #BrainHealth #TraumaInformed #PolicyChange #CommunityHealth #SocialDeterminantsOfHealth #CollaborativeLeadership #EconomicMobility #EducationEquity #HealthcareInnovation #DataDrivenPolicy #CommunityDevelopment

To learn more about the breakthroughs discussed in this episode and to support ongoing research, visit our website at tofflertrust.org.

Technical Podcast Support by Jon Keur at Wayfare Recording Co.

Welcome back to Research Renaissance, presented by the Karen Toffler Charitable Trust. In this episode, host Deborah Westphal explores the cutting edge of rare disease research with special guests Andrew Rosen, CEO of the National Ataxia Foundation (NAF), and Dr. Lauren Moore, NAF’s Chief Scientific Officer.

Together, they unpack how the NAF has evolved from a small support-focused nonprofit into a strategic, science-driven organization that’s advancing treatments and reshaping what’s possible for people living with ataxia—a rare, progressive neurological condition affecting movement and coordination.

🔍 In this episode, we explore:

• The history and mission of the National Ataxia Foundation—from its 1957 founding to its current research initiatives
• What ataxia is, how it’s diagnosed, and why it’s so often misunderstood or misdiagnosed
• The diagnostic odyssey patients face and how genetic testing is both essential and still evolving
• How patient advocacy, family involvement, and rare-disease communities are accelerating the pace of scientific discovery
• Lauren’s personal journey from biomedical physics student to ataxia researcher—sparked by her father’s diagnosis
• Why wearable tech, remote trials, and AI are changing the game for neurological research
• The power of public-private partnerships and how the first FDA-approved ataxia treatment led to a $7.3B acquisition by Biogen
• Why “rare” doesn’t mean small—and why rare diseases deserve different standards of study, funding, and approval
  
  

🧠 Key Takeaway:

Treatments are on the horizon—but getting there takes relentless advocacy, strategic funding, and courageous participation from patients and families. As Andrew puts it: “We’d love to put ourselves out of business someday. Until then, we’re here to build the infrastructure that gets us there.”

🌐 Resources & Links:

• National Ataxia Foundation (NAF)
• Karen Toffler Charitable Trust
• Learn more about hereditary ataxias and ongoing research initiatives
• Support or participate in patient-driven research and advocacy

🎧 Subscribe to Research Renaissance
 Available on Apple Podcasts, Spotify, and all major platforms. For more conversations at the intersection of neuroscience, technology, and purpose-driven science, follow us at tofflertrust.org or get in touch.

To learn more about the breakthroughs discussed in this episode and to support ongoing research, visit our website at tofflertrust.org.

Technical Podcast Support by Jon Keur at Wayfare Recording Co.

In this groundbreaking episode of Research Renaissance, host Deborah Westphal reconnects with Dr. Adithya Gopinath, University of Florida, to explore a game-changing discovery in Parkinson’s research: a direct connection between dopamine neurons in the brain and the peripheral immune system, specifically the spleen.

Dr. Gopinath shares how his lab’s findings could reshape the future of Parkinson’s diagnosis and treatment—potentially identifying the disease earlier and opening new therapeutic avenues using existing immune-modulating drugs. The episode also touches on surprising implications for conditions like addiction, ADHD, and even cancer.

Key Topics Covered:

• The role of dopamine transporters in both the brain and peripheral immune cells
• A newly mapped brain-to-spleen pathway and its implications for Parkinson’s
• Why gastric bypass surgery offers unexpected clues about neuroimmune function
• How Parkinson’s might eventually be detected through blood biomarkers
• The challenge of longitudinal studies and the need for philanthropic support
• Crossovers with autoimmune disease, glioblastoma, and methamphetamine use
• The future vision for translational research at Dr. Gopinath’s lab
  
  

Standout Quote:
 "If we're able to identify Parkinson’s early, we may have the opportunity to either slow or stop its progression. And we might already have the tools—we just need to apply them in the right way." – Dr. Adithya Gopinath

Connect with Us:
 🔗 Learn more and subscribe: https://tofflertrust.org
📧 Interested in supporting or collaborating? Dr. Gopinath’s contact info: adithya.gopinath@neurology.ufl.edu or adithya@ufl.edu 

To learn more about the breakthroughs discussed in this episode and to support ongoing research, visit our website at tofflertrust.org.

Technical Podcast Support by Jon Keur at Wayfare Recording Co.

In this episode of Research Renaissance, Deborah Westphal sits down with Dr. Grant Mitchell, co-founder and CEO of Every Cure — a nonprofit revolutionizing how we treat disease using artificial intelligence and drug repurposing.

You’ll hear the incredible true story behind the organization’s founding: a rare disease, a near-death diagnosis, and the life-saving power of finding the right drug at the right time — one that was already FDA-approved but never intended for that disease.

Dr. Mitchell unpacks how Every Cure is:

• Using AI to map connections between 4,000+ FDA-approved drugs and 20,000+ diseases.
• Tackling the “organizational problem” in medical research — not just the scientific one.
• Building a nonprofit model that bypasses commercial incentives to focus purely on patient outcomes.
• Launching a new public platform that will allow researchers, doctors, and even patients to explore potential drug-disease matches.

💡 From real-world case studies to a bold vision for transforming clinical trial timelines, this is an inspiring and eye-opening look at how a small team might just be out-innovating Big Pharma — and doing it faster, cheaper, and with more heart.

Resources Mentioned:

• Visit everycure.org to learn more or get involved.
• Contact Grant directly at grant@everycure.org
• Learn more about the Karen Toffler Charitable Trust at tofflertrust.org

Never miss an episode of Research Renaissance — subscribe on your favorite podcast platform and follow us at tofflertrust.org for updates.

To learn more about the breakthroughs discussed in this episode and to support ongoing research, visit our website at tofflertrust.org.

Technical Podcast Support by Jon Keur at Wayfare Recording Co.

In this powerful episode of Research Renaissance, host Deborah Westphal sits down with Dr. Rachel Buckley, Associate Professor of Neurology at Massachusetts General Hospital and Harvard Medical School. Together, they explore a growing body of research that challenges long-standing assumptions about sex differences in Alzheimer's disease.

Dr. Buckley shares her unexpected journey from skepticism to advocacy in studying how biological sex and hormonal changes—particularly around menopause—can influence Alzheimer's risk, pathology, and progression. From PET scans to postmortem tissue studies, she unpacks what we now know about tau pathology in women, the role of hormone therapy, and how reproductive history may shape brain health.

You’ll also hear about:

• Why women are disproportionately impacted by Alzheimer’s—and why it’s more than just longevity
• How timing of hormone therapy may impact tau buildup
• Surprising research around pregnancy, caregiving, and even the X chromosome
• Where the research gaps still exist—and how AI might help close them
• Why training the next generation of sex-based neuroscientists is essential

Whether you’re a caregiver, clinician, researcher, or simply curious about how brain health intersects with gender, this episode offers eye-opening insight and hope for the future.

Guest Bio:
 Dr. Rachel Buckley is an internationally recognized neuroscientist focused on the intersection of sex differences and Alzheimer's disease. She leads groundbreaking research at Massachusetts General Hospital and serves as Chair of the Alzheimer’s Association’s Sex and Gender Professional Interest Area.

Resources & Links:
 🔗 Learn more: https://www.tofflertrust.org
📧 Contact Dr. Buckley via email or LinkedIn
💡 Alzheimer’s Association: https://www.alz.org

Subscribe & Follow:
Don’t miss upcoming episodes—subscribe wherever you listen to podcasts and follow us on social for updates.

To learn more about the breakthroughs discussed in this episode and to support ongoing research, visit our website at tofflertrust.org.

Technical Podcast Support by Jon Keur at Wayfare Recording Co.

In this episode of Research Renaissance, host Deborah Westphal sits down with Dr. Prabesh Bhattarai, Associate Research Scientist - The Taub Institute for Research on Alzheimer's Disease, the aging Brain, Columbia University Irving Medical Center and a 2024 Toffler Scholar.

Dr. Bhattarai shares his groundbreaking work on regenerative biology and how understanding the remarkable ability of certain fish to regrow neurons could eventually lead to new treatments for neurodegenerative diseases like Alzheimer’s.

They explore:

🧠 How the fish geography can regenerate neurons lost to Alzheimer-like damage
🧬 The role of signaling molecules like IL-4 and BDNF in promoting brain regeneration
🐭 Why these regenerative processes don’t naturally occur in mice or humans—and what happens when researchers try to induce them
🔍 How astrocytes and the blood-brain barrier play a key role in Alzheimer’s pathology
🧪 How single-cell and spatial transcriptomics are unlocking new insights into brain cell function
🕵️‍♂️ The importance of identifying early biomarkers for Alzheimer’s to enable earlier intervention
🧩 Why Alzheimer’s is a multifactorial disease that requires a broad, integrative research approach
🔮 The future of therapeutic strategies—and the potential for delaying or even preventing disease progression

Dr. Bhattarai also discusses his latest findings around fibronectin 1 as a promising therapeutic target, and the complex but hopeful road ahead in Alzheimer’s research.

👉 If you’d like to learn more about Dr. Bhattarai’s work or connect with him, you can reach him at: pb2886@cumc.columbia.edu

🎧 Stay tuned for more episodes of Research Renaissance—exploring the future of brain science.

Visit tofflertrust.org to subscribe and learn more about the Karen Toffler Charitable Trust and its mission to advance cutting-edge brain research.

To learn more about the breakthroughs discussed in this episode and to support ongoing research, visit our website at tofflertrust.org.

Technical Podcast Support by Jon Keur at Wayfare Recording Co.

In this exciting episode of Research Renaissance, host Deborah Westphal speaks with Dr. Ted Zwang, Assistant Professor of neurology at Massachusetts General Hospital and Harvard Medical School, Dr. Andrew Holbrook, Assistant Professor at UCLA and Jasen Zhang, PhD student in biostatistics in Holbrook’s lab. Together, they share how novel neural recording devices and advanced machine learning techniques are transforming the study of Alzheimer’s disease.

Dr. Ted and Jasen discuss their collaborative project—funded by the Kavli Foundation, Cure Alzheimer’s Fund, and the Karen Toffler Charitable Trust—which captures how neurons change over time in Alzheimer’s mouse models. They reveal surprising discoveries about how some neurons “go quiet” and later recover—challenging long-held assumptions about neurodegeneration.

The conversation also explores how these insights could lead to earlier diagnostics, predictive models of cognitive decline, and more personalized treatments for patients.

🔬 Topics include:
 - How flexible neural recording devices track neuron activity over months
 - Why biostatistics and machine learning is key to decoding massive neural datasets
-  New findings about reversible neuronal dysfunction in Alzheimer’s
-  How predictive models could inform personalized medicine
-  The challenges of translating animal research to human diagnostics
-  The importance of interdisciplinary collaboration in brain science

Whether you’re a researcher, student, clinician, or curious learner, this episode offers a glimpse into the future of Alzheimer’s research—and why there’s new reason for hope.

🧠 Guests: Dr. Ted Zwang https://zwanglab.com/, Dr. Andrew Holbrook https://andrewjholbrook.github.io/ and Jasen Zhang https://www.linkedin.com/in/jasen-zhang/
🌐 For more episodes and updates, visit: tofflertrust.org

To learn more about the breakthroughs discussed in this episode and to support ongoing research, visit our website at tofflertrust.org.

Technical Podcast Support by Jon Keur at Wayfare Recording Co.

In this fascinating episode of Research Renaissance, host Deborah Westphal sits down with Dr. Heather Brenhouse, professor of psychology and director of the Developmental Neuropsychobiology Lab at Northeastern University—and a 2024 Toffler Scholar. Together, they explore the deep connections between childhood adversity, brain development, and long-term mental health.

Dr. Brenhouse discusses why early life stress impacts some individuals more than others, how adversity can alter the timing of puberty, and why understanding neurodevelopment is essential to preventing psychiatric disorders. They also delve into the biology of behavior, the role of immune cells in the brain, and how evolving tools in neuroscience are helping uncover hidden patterns that shape health outcomes later in life.

🔬 Topics include:

• What a neuropsychobiology lab really studies
• How early stress accelerates brain and body development
• The surprising link between early adversity and puberty
• Why male and female brains respond differently to early life challenges
• How microglia and inflammation relate to long-term brain health
• The future of neuroscience research—from metabolic studies to computational modeling
• How eastern and western medicine might converge around mind-body health
  
  
  

Whether you're a researcher, student, or curious lifelong learner, this episode sheds light on how early experiences shape us—and what that means for preventing disease and promoting wellness across a lifetime.

🧠 Guest: Dr. Heather Brenhouse
 🔗 Learn more: brenhouselab.sites.northeastern.edu
 📧 Contact: h.brenhouse@northeastern.edu

🌐 For more episodes and updates, visit: tofflertrust.org

To learn more about the breakthroughs discussed in this episode and to support ongoing research, visit our website at tofflertrust.org.

Technical Podcast Support by Jon Keur at Wayfare Recording Co.

In this fascinating episode of Research Renaissance, host Deborah Westphall welcomes Dr. Alysson Muotri,  a professor in the Departments of Pediatrics and Cellular & Molecular Medicine at the University of California, San Diego., for a deep dive into what makes the human brain unique—and how understanding that uniqueness might unlock new treatments for neurological disorders. From stem cell brain models grown in the lab to sending "mini-brains" into space, Dr. Muotri shares his bold, unconventional path to advancing neuroscience and personalized medicine.

Dr. Muotri discusses his work creating 3D brain organoids to model human neurological development, including conditions like autism and epilepsy. He explains how modern humans evolved slower brain development than our ancestors, and how that developmental window leaves us vulnerable to mutation and disease—but also offers the complexity that makes human cognition and collaboration possible.

The conversation also touches on ethical frontiers, including the potential for lab-grown brains to develop consciousness, the future of neuroscience in space, and how traditional Amazonian medicine may offer clues to protecting the brain.

In This Episode:

• Why collaboration and sociality are key traits of the human brain
• How brain organoids help us study disorders like autism without invasive methods
• Using Neanderthal DNA to uncover what’s uniquely human
• Why space accelerates brain aging—and how that might fast-track drug discovery
• The ethical questions we must face as lab-grown brain tissues become more advanced
• How Dr. Muotri’s personal journey as a father shaped his scientific mission
• The need for alternative funding models to support bold, high-risk science

Quotes to Remember:
🧠 “We’re not just studying the brain. We’re building avatars of it.”
🚀 “Thirty days in space aged our brain organoids by ten years.”
🧬 “Autism may be the price we pay for having evolved a social brain.”
🌱 “Maybe the cure for Alzheimer’s is growing in the Amazon. We just have to look.”

Links & Resources:

• Learn more about Dr. Muotri’s lab: [Search “Alysson Muotri UCSD”]
• Explore the Karen Toffler Charitable Trust: https://tofflertrust.org
  
  
  

Connect with Us:
 💬 Have feedback or want to get involved? Reach out via our website or social channels.
 🔔 Don’t miss an episode—subscribe now on Spotify, Apple Podcasts, or your favorite podcast app.

To learn more about the breakthroughs discussed in this episode and to support ongoing research, visit our website at tofflertrust.org.

Technical Podcast Support by Jon Keur at Wayfare Recording Co.

In this episode of Research Renaissance, host Deborah Westphal welcomes Dr. Yvette Wong, Assistant Professor of Neurology at Northwestern University and 2024 Toffler Scholar, for a deep dive into the dynamic inner world of cells—and how her lab is uncovering new clues about neurodegenerative diseases by studying the microscopic interactions between organelles.

Dr. Wong discusses how organelles like mitochondria and lysosomes don’t just function in isolation—they actually “talk” to each other at contact points within cells. These cellular conversations may hold the key to unlocking better understanding and treatments for conditions like ALS, Parkinson’s, and Huntington’s disease.

Through vivid analogies (like buses exchanging cargo), Dr. Wong helps translate complex science into clear visuals, while also highlighting how advances in super-resolution live-cell microscopy and data analysis are transforming what’s possible in neuroscience.

🔬 Topics Covered:

• What organelles and organoids are—and why they matter
• The importance of mitochondrial-lysosomal contact sites in brain cells
• How defects in organelle crosstalk may contribute to diseases like ALS and Parkinson’s
• Why time-lapse microscopy is revolutionizing our understanding of disease mechanisms
• How Huntington’s disease mutations affect cellular cleanup systems
• The promise (and challenge) of modeling decades-long diseases in a lab
• Dr. Wong’s vision for the future of neuroscience—and the dream experiment she hopes technology will make possible

🔗 Resources & Links:

• Dr. Yvette Wong’s Lab: [Search “Yvette Wong Lab” or visit Northwestern University Feinberg School of Medicine]
• Learn more about the Karen Toffler Charitable Trust: https://tofflertrust.org/
  📬 Contact Dr. Wong:
   Email: yvette.wong@northwestern.edu

🎧 Subscribe & Follow:
 For more episodes and breakthroughs in brain science, subscribe to Research Renaissance and follow the Karen Toffler Charitable Trust on your favorite podcast platform.

To learn more about the breakthroughs discussed in this episode and to support ongoing research, visit our website at tofflertrust.org.

Technical Podcast Support by Jon Keur at Wayfare Recording Co.

In this compelling episode of Research Renaissance, host Deborah Westphal sits down with Sue Peschin, President and CEO of the Alliance for Aging Research, for a candid conversation about the intersection of science, policy, and aging. From Alzheimer’s drug coverage to the future of stem cell research, they unpack what it truly means to age with dignity—and how equity, access, and advocacy play a critical role.

Sue shares her personal journey into aging research, her leadership transition at the Alliance, and the organization’s long-standing commitment to ensuring older adults receive fair and effective healthcare. They explore the challenges of Coverage with Evidence Development (CED) in Medicare, the rising need for culturally competent communication, and how the stigma around neuropsychiatric symptoms in aging can be addressed through education and empathy.

Key Topics Covered:

• The origins and mission of the Alliance for Aging Research
• Medicare’s use of “Coverage with Evidence Development” for Alzheimer’s therapies
• Challenges in equitable access to aging-related treatments
• The political and scientific landscape of stem cell research
• Outreach strategies for underserved and underrepresented aging populations
• Neuropsychiatric symptoms in dementia and the importance of caregiver education
• Mental health trends in older adults and increasing substance use concerns
• The role of policy, education, and interdisciplinary collaboration in advancing healthy aging

Memorable Quote:
 “Everybody deserves to age as healthy as they can.” – Sue Peschin

Resources & Links:
 🔗 Alliance for Aging Research
📧 Contact Sue: speshin@agingresearch.org
📺 YouTube: Alliance for Aging Research Video Library
🔬 Learn more about our mission at TofflerTrust.org

To learn more about the breakthroughs discussed in this episode and to support ongoing research, visit our website at tofflertrust.org.

Technical Podcast Support by Jon Keur at Wayfare Recording Co.

In this eye-opening episode of Research Renaissance, Dr. Rod Scott takes us on a journey through the emerging science of brain networks, complex adaptive systems, and why rethinking how we treat neurological conditions like epilepsy and autism might be the key to improving outcomes—especially in children.

Dr. Scott explains why he views the brain not as a collection of isolated parts, but as a dynamic, self-organizing system. From his clinical experience to his cutting-edge lab work on neural firing patterns and cognitive behavior, he shares why focusing on repairing brain networks—rather than treating individual genes or symptoms—could reshape our entire approach to neurological care.

Key highlights include:

• 🧠 Why traditional “gene-to-cure” models often fall short in treating epilepsy and autism
• 🧬 How complex systems thinking offers a more holistic—and promising—framework for brain health
• ⚡ Dr. Scott’s experimental work with electrical brain stimulation to restore cognitive function in mouse models
• 🧒 Why he focuses more on quality of life than stopping every seizure in pediatric epilepsy treatment
• 💡 The surprising effects of environmental enrichment on malformed brain networks

Whether you're a clinician, researcher, or simply curious about the future of neuroscience, this episode offers a radically different perspective on what it means to heal the brain.

Resources & Links:

• Learn more about Nemours Children’s Hospital: nemours.org
• Contact Dr. Rod Scott: rodney.scott@nemours.org
• Explore the Karen Toffler Charitable Trust: tofflertrust.org

Connect with Us: 💌 Subscribe to the show for more thought-provoking interviews
 🌐 Visit our website: tofflertrust.org
📲 Follow us on LinkedIn

To learn more about the breakthroughs discussed in this episode and to support ongoing research, visit our website at tofflertrust.org.

Technical Podcast Support by Jon Keur at Wayfare Recording Co.

In this episode of Research Renaissance, host Deborah Westphal sits down with Dr. Frank Furnari, professor of medicine at UC San Diego and co-director of the Brain Tumor Program at the Sanford Stem Cell Institute. Together, they explore one of the most aggressive and complex cancers known to medicine—glioblastoma—and the innovative tools his team is developing to study and treat it.

🔬 Topics Covered:

• Why glioblastoma is so resistant to treatment—and what makes it unique
• The role of tumor heterogeneity and how “chameleon-like” cancer cells adapt
• How Dr. Furnari’s lab uses CRISPR-edited stem cells and “cancer avatars” to model brain tumors in mice and organoids
• Promising breakthroughs in radiation sensitization and tumor state manipulation
• CAR-T cells therapies, BRD2 inhibitors, and the future of personalized brain cancer vaccines
• The emerging field of cancer neuroscience—and how neuron-tumor interactions may hold new clues to treatment
• The cost and complexity of running a modern lab and the growing need for diversified funding
• Why partnerships across disciplines (immunology, bioengineering, AI, bioinformatics) are essential for accelerating breakthroughs

💡 Dr. Furnari also reflects on his career beginnings, his leadership philosophy, and what excites him most about the future of brain cancer research.

🔗 Connect with Dr. Frank Furnari:

• Website: Search “Furnari Lab UCSD” (not a real link – adjust as needed)
• Email: ffan@ucsd.edu
• LinkedIn: Frank Furnari (link placeholder)
• Twitter/X: @FurnariLab

🧠 May is Brain Tumor Awareness Month
 Join the conversation, share this episode, and help raise awareness about the urgent need for brain cancer research and funding.

To learn more about the breakthroughs discussed in this episode and to support ongoing research, visit our website at tofflertrust.org.

Technical Podcast Support by Jon Keur at Wayfare Recording Co.

In this compelling episode of Research Renaissance, host Deborah Westphal sits down with Jackson Mace, a neuroscience PhD candidate at Johns Hopkins University and 2023 Toffler Scholar, to explore the cutting-edge research driving our understanding of neurodegenerative diseases—particularly multiple sclerosis (MS).

Drawing from personal experience—his father’s MS diagnosis—and a deep academic curiosity, Jackson shares the winding path that led him from undergraduate lab work to a promising career in neuroimmunology. Together, they discuss:

🧠 Why MS is more than just an autoimmune condition—and how it’s being reframed as a neurodegenerative disease
 🧪 The experimental models Jackson uses to study gray matter lesions and cell death in the brain, spinal cord, and eyes
 🧬 His work on a little-known but powerful cell death pathway known as Parthanatos, and how it could unlock new therapeutic strategies
 💊 A behind-the-scenes look at how early research and seed funding (including support from the Karen Toffler Charitable Trust) fuels long-term breakthroughs
 🌍 The critical role of interdisciplinary collaboration between neuroscience, immunology, and pharmacology
 🗣️ Why scientific communication and mentorship matter just as much as lab results

Whether you're a fellow researcher, a curious patient advocate, or simply fascinated by the future of brain science, this episode sheds light on the personal and professional forces driving the next generation of neuroscience discovery.

👤 Guest:
 Jackson Mace, Neuroscience PhD Candidate, Johns Hopkins University
 📍LinkedIn: Jackson Mace
📧 Email: jackson.w.mace@gmail.com

🔗 Learn more about the show and the Karen Toffler Charitable Trust:

https://tofflertrust.org/ 

To learn more about the breakthroughs discussed in this episode and to support ongoing research, visit our website at tofflertrust.org.

Technical Podcast Support by Jon Keur at Wayfare Recording Co.

In this episode of Research Renaissance, host Deborah Westphal sits down with Dr. Alberto Serrano-Pozo, Assistant Professor of Neurology at Harvard Medical School, staff neurologist at Massachusetts General Hospital, and a 2022 Toffler Scholar. Together, they explore Dr. Serrano-Pozo’s pioneering research into the role of glial cells—specifically astrocytes—and the APOE gene in the development and progression of Alzheimer’s disease.

Dr. Serrano-Pozo discusses how astrocytes, long overlooked in favor of neurons, are now recognized as key players in maintaining brain health—and how their dysfunction may contribute to Alzheimer's pathology. The conversation also covers the complexities of the APOE gene variants, how recent discoveries are reshaping our understanding of Alzheimer's across different populations, and promising advances in gene-editing research.

Dr. Serrano-Pozo also reflects on the dual role he plays as both a researcher and a clinician, how patient interactions inspire his lab work, and why cautious optimism is warranted as new therapies and technologies emerge.

What You'll Learn:

• Why astrocytes are crucial to brain function—and how they change in Alzheimer's
• The evolving understanding of the APOE gene’s role in Alzheimer's risk
• How glial cells interact with amyloid plaques and tau tangles
• Why certain APOE variants affect populations differently
• Advances in gene-editing that may offer future protection against Alzheimer's
• The real-world challenges and rewards of balancing clinical practice with research
• A hopeful look at the accelerating pace of Alzheimer's research and innovation

Key Quotes:
 🧠 "If we can understand how astrocytes get sick, maybe we can fix them—and slow the progression of Alzheimer's."
 🧬 "APOE is like a messenger between brain cells—and one small genetic variation can change everything."
 🌎 "There's more collaboration, more knowledge-sharing, and more technological advancement than ever before. We should remain cautiously optimistic."

Learn More:
🔗 Visit tofflertrust.org to stay updated on future episodes and initiatives.

To learn more about the breakthroughs discussed in this episode and to support ongoing research, visit our website at tofflertrust.org.

Technical Podcast Support by Jon Keur at Wayfare Recording Co.

In this illuminating episode of Research Renaissance, host Deborah Westphal sits down with Ana Maiques, CEO and co-founder of Neuroelectrics, a groundbreaking company at the forefront of non-invasive brain stimulation technology. Together, they explore the intersection of neuroscience, entrepreneurship, and innovation, diving deep into how electrical brain stimulation is changing the future of treatment for neurological disorders like epilepsy, depression, and Alzheimer’s.

Ana shares her unconventional journey into entrepreneurship, her commitment to ethical tech, and the long road to FDA approval. She also discusses the development of Neuroelectrics’ personalized brain therapies and the potential for at-home use of medical-grade neurostimulation devices.

📌 Resources & Mentions:

• Neuroelectrics
• Karen Toffler Charitable Trust
• The Termeer Foundation
• AI and Neuroethics Summit with President Macron
• Brain Digital Twin / Neurotwin platform

📫 Stay Connected

Connect with Ana Maiques:
 📧 ana.maiques@neuroelectrics.com
 🔗 LinkedIn – Neuroelectrics

Follow Research Renaissance:
 🌐 tofflertrust.org
🎧 Subscribe on your favorite podcast platform
📞 Contact us with ideas or questions!

To learn more about the breakthroughs discussed in this episode and to support ongoing research, visit our website at tofflertrust.org.

Technical Podcast Support by Jon Keur at Wayfare Recording Co.

In this episode of Research Renaissance, host Deborah Westphal is joined by Meg Smith, the Chief Executive Officer of Cure Alzheimer’s Fund. They dive deep into the innovative and high-impact research Cure Alzheimer’s Fund is supporting to prevent, slow, and ultimately cure Alzheimer’s disease. Meg shares her fascinating career journey from law and consulting to leading an organization that is revolutionizing brain disease research.

Together, they discuss:
 ✅ The unique funding model of Cure Alzheimer’s Fund and why it accelerates research breakthroughs
 ✅ The biggest challenges in Alzheimer’s research and how philanthropic funding is filling critical gaps
 ✅ Exciting cutting-edge research on gut microbiome, the immune system, and the role of sleep in brain health
 ✅ The importance of high-risk, high-reward funding in pushing scientific discovery forward
 ✅ How the organization supports researchers and ensures their focus remains in the lab, not on fundraising

Resources & Links:

🔗 Learn more about Cure Alzheimer’s Fund: www.curealz.org
📧 Contact Meg Smith: msmith@curealz.org
🔬 Researchers: Submit inquiries to grants@curealz.org
🌍 Stay connected with the Karen Toffler Charitable Trust: www.tofflertrust.org

🎧 Listen & Subscribe:
 Subscribe to Research Renaissance for more inspiring conversations on the future of neuroscience and research innovation.

🔔 Don’t forget to rate and review! If you enjoyed this episode, share it with your network and help us spread the word about advancing brain science.

To learn more about the breakthroughs discussed in this episode and to support ongoing research, visit our website at tofflertrust.org.

Technical Podcast Support by Jon Keur at Wayfare Recording Co.

Can oxygen levels in the brain help explain Alzheimer’s disease? In this episode of Research Renaissance, host Deborah Westphal sits down with Dr. Nancy E. Ruiz, a Harvard Medical School research fellow and 2023 Toffler Scholar, to explore a powerful yet underexamined piece of the Alzheimer’s puzzle: vascular dysfunction.

Dr. Ruiz shares how her background in physics and biology led her to cutting-edge brain research using advanced imaging tools like two-photon phosphorescence lifetime imaging. Together, they dive into how oxygenation, blood flow, and lifestyle factors such as exercise and diet may hold the key to prevention — and why we must look beyond amyloid and tau to fully understand the disease.

Plus, hear Dr. Ruiz’s insights on the importance of interdisciplinary collaboration, working with human brain tissue, and how she balances scientific rigor with pottery, running, and a good meal.

📌 Don’t forget to follow and rate the show!
New episodes explore the people, breakthroughs, and bold ideas shaping the future of brain science.

To learn more about the breakthroughs discussed in this episode and to support ongoing research, visit our website at tofflertrust.org.

Technical Podcast Support by Jon Keur at Wayfare Recording Co.

In this episode of Research Renaissance, host Deborah Westphal sits down with Catharine Smith, Executive Director of the Termeer Foundation, to explore innovation in the biotech industry and the evolving role of leadership. They dive into how biotech leaders are shaping the future of healthcare, supporting emerging companies, and addressing rare diseases.

Key Topics Covered

• Catharine Smith’s Career Journey – From health services research to leading an influential foundation supporting biotech leaders.
• Biotech Leadership & Change Agents – What makes a great leader in the biotech space and how leadership is evolving.
• Henri Termeer’s Legacy – How the Termeer Foundation was founded and its impact on patient-centered biotech innovation.
• Supporting Biotech CEOs – Challenges, common needs, and how the foundation mentors and funds early-stage biotech leaders.
• Rare Disease & Patient Advocacy – The role of patient-driven biotech innovation and the partnerships making breakthroughs possible.
• Future of Biotech & Leadership – How AI, innovation, and a stronger emphasis on leadership will shape the next generation of biotech advancements.

Memorable Quotes
🗣️ "The most effective biotech leaders are driven by an internal ‘why’—a passion for improving patient care and making an impact." – Catharine Smith

🗣️ "If we look at rare diseases as a collective, they’re not rare at all. The unmet need is massive, and we’re seeing patient advocates leading the way in finding solutions." – Catharine Smith

Resources & Mentions

• Termeer Foundation: termeerfoundation.org
• Book Recommendation: Conscience and Courage – The story of Henri Termeer’s life and legacy.
• Rare Disease Advocacy: Learn more about patient-led biotech innovations and advocacy groups.

Connect With Us

📌 Follow Research Renaissance: Website | LinkedIn
📌 Follow Catharine Smith & The Termeer Foundation: LinkedIn

💡 Enjoyed the episode? Subscribe, leave a review, and share it with colleagues interested in biotech innovation and leadership!

🔍 Want to learn more or collaborate? Contact Karen Toffler Charitable Trust via our website or LinkedIn

🎧 Listen & Subscribe: Available on Spotify, Apple Podcasts, and other major platforms.

Until next time—onward and upward! 🚀

To learn more about the breakthroughs discussed in this episode and to support ongoing research, visit our website at tofflertrust.org.

Technical Podcast Support by Jon Keur at Wayfare Recording Co.

In this episode of Research Renaissance, host Deborah Westphal welcomes Dr. Carrie Wolinetz, a leading science and health policy expert. With an extensive background, including roles at the National Institutes of Health (NIH) and the White House Office of Science and Technology Policy, Dr. Wolinetz shares her insights on the evolving landscape of medical research funding, the role of science policy, and the critical intersection between government, private sector, and research institutions.

From the historical foundations of federally funded science to the challenges posed by shifting political landscapes, Dr. Wolinetz offers a compelling perspective on the future of research and public health.

What You’ll Learn in This Episode

🔬 The Role of Science Policy: How policy shapes the research ecosystem and why it’s essential for medical advancements.
🧬 The Impact of Federally Funded Research: The return on investment from initiatives like the Human Genome Project and how they’ve revolutionized medicine.
🌎 The Changing Landscape of Research Funding: How federal funding priorities are shifting and what researchers need to prepare for.
💰 The Future of Public-Private Partnerships: How government, academia, and the private sector must collaborate to accelerate breakthroughs.
⚖️ The Debate on Indirect Costs (F&A Rates): Understanding the recent policy changes and their impact on research institutions.
📢 The Importance of Science Communication: Why researchers must engage in public discussions to build trust and transparency.
🧑‍🔬 Advice for Early-Career Researchers: How young scientists can navigate funding uncertainties and thrive in a rapidly evolving research environment.
💡 The Next Frontier in Public Health: What’s needed to create a robust and proactive health infrastructure for future global challenges.

Key Quotes from Dr. Carrie Wolinetz

💭 “Science is all about solving problems. The best research happens when patients, researchers, and policymakers work together.”

💭 “The Human Genome Project had a 141-to-1 return on investment—nearly a trillion dollars in impact.”

💭 “Science isn’t just about discovery; it’s about making sure discoveries lead to real-world impact.”

💭 “We need a new national vision for public health—one that integrates the lessons of COVID-19 and prioritizes rapid response to emerging threats.”

Resources & Links

📌 Karen Toffler Charitable Trust: tofflertrust.org
📌 Dr. Carrie Wolinetz on LinkedIn: LinkedIn Profile
📌 NIH Office of Science Policy: NIH Science Policy
📌 The 100-Day Mission for Pandemic Preparedness: Learn More

Stay Connected

📢 Subscribe for More Episodes! Stay informed on groundbreaking research and policy discussions shaping the future of science.
🌐 Visit tofflertrust.org for updates and initiatives.
📩 Have thoughts or questions? Reach out to us—we’d love to hear from you!

🎧 Listen & Subscribe on Your Favorite Platform
📌 Apple Podcasts | Spotify | Google Podcasts | Stitcher | Amazon Music

🚀 Until next time—onward and upward!

To learn more about the breakthroughs discussed in this episode and to support ongoing research, visit our website at tofflertrust.org.

Technical Podcast Support by Jon Keur at Wayfare Recording Co.

Welcome to Research Renaissance, presented by the Karen Toffler Charitable Trust. In this episode, host Deborah Westphal sits down with Dr. Kasper Roet, CEO and co-founder of QurAlis, to explore the evolution of ALS drug development, the power of genetic insights, and the future of personalized medicine for neurodegenerative diseases.

🔬 Episode Highlights:

✔️ From Spinal Cord Injury to ALS – Dr. Roet’s journey from spinal cord injury research to ALS, and how genetic discoveries reshaped his focus.
✔️ A New Era for Drug Development – The pivotal role of genomics, AI, and stem cell technology in accelerating ALS treatments.
✔️ Precision Medicine & Stem Cells – How patient-derived pluripotent stem cells are transforming ALS research.
✔️ Cure ALS: The Mission & Breakthroughs – The pioneering therapies Quralis is developing to target ALS at the molecular level.
✔️ Challenges in Biotech Entrepreneurship – The leap from scientist to CEO, raising funds, and the mentorship that helped shape his journey.
✔️ The Future of Neurological Disease Research – What’s next for genetic medicine, biomarkers, and targeted treatments?

💡 Key Takeaways:

🔹 ALS is no longer a “mystery disease” – recent genetic breakthroughs are leading to targeted treatments.
🔹 Traditional animal models are failing to replicate human disease—patient-derived stem cells are offering a more reliable solution.
🔹 The intersection of AI, big data, and molecular biology will drive the next wave of personalized medicine.
🔹 Biotech innovation demands a balance between scientific rigor and entrepreneurial agility.
🔹 The industry must shorten drug development timelines to bring life-saving treatments to patients faster.

🎧 Listen Now & Subscribe!

Stay ahead in the world of cutting-edge neuroscience and biotech breakthroughs. Subscribe to Research Renaissance on your favorite podcast platform and visit TofflerTrust.org for more insights.

🔗 Want to collaborate or learn more? Connect with Dr. Kasper Roet and his team at Quralis or email info@quralis.com.

🚀 Join us in advancing the future of brain research—because patients can’t wait!

To learn more about the breakthroughs discussed in this episode and to support ongoing research, visit our website at tofflertrust.org.

Technical Podcast Support by Jon Keur at Wayfare Recording Co.

In this thought-provoking episode of Research Renaissance, host Deborah Westphal welcomes Dr. Melissa Flagg, an advisor for the Andrew W. Marshall Foundation and a research fellow at the Acquisition Innovation Research Center. Dr. Flagg has had an extensive career spanning government, academia, and the private sector, including her role as Deputy Assistant Secretary of Defense for Research.

Together, they explore the evolving landscape of research and development (R&D) in the U.S. and beyond. They discuss the history, funding models, and gaps in the system, as well as new opportunities to connect scientific research with real-world applications. Dr. Flagg also offers a candid perspective on how research institutions prioritize funding, the challenges faced by early-career researchers, and the growing influence of industry and philanthropy in driving scientific innovation.

💡 Key Topics Discussed:
✅ The complexity of the U.S. research ecosystem and how it has evolved since WWII
✅ The shift from federal government dominance in R&D to industry-driven funding
✅ The gap between academic research and real-world solutions—why so many discoveries remain unused
✅ The replication crisis and the challenges of publishing scientific research
✅ How patient advocacy groups and regional initiatives can reshape research funding
✅ Why the U.S. needs new funding models to prioritize impact over publications
✅ The need for better compensation for researchers to improve the quality of scientific output
✅ Why philanthropy and communities should play a larger role in directing research efforts

📢 Memorable Quotes from Dr. Melissa Flagg:
🗣️ “We need to stop prioritizing scale and proxy measures of success like publications and focus on real impact.”
🗣️ “Basic research is critical, but without application pathways, it won’t help anyone.”
🗣️ “If we want high-quality research, we need to pay scientists what they’re worth.”
🗣️ “There’s no single list of everyone who might be interested in what you’re doing—you have to actively find your people.”

🎧 Tune in to hear a powerful conversation on the past, present, and future of research!

🔗 Connect with Dr. Melissa Flagg:

• Website: www.flaggconsulting.com
• LinkedIn: Melissa Flagg

📍 Learn More:
Visit the Karen Toffler Charitable Trust for more insights into neurological research and innovation: www.tofflertrust.org

💡 Join the Conversation:
Have thoughts or ideas? Subscribe, leave a review, and let us know what topics you’d love to hear next!

🎙️ Listen Now! 🚀

To learn more about the breakthroughs discussed in this episode and to support ongoing research, visit our website at tofflertrust.org.

Technical Podcast Support by Jon Keur at Wayfare Recording Co.

In this enlightening episode of Research Renaissance, host Deborah Westphal sits down with Dr. Dean Ornish, founder of the Preventative Medicine Research Institute and a pioneer in lifestyle medicine. Dr. Ornish shares groundbreaking research on how lifestyle changes—including diet, exercise, stress management, and social connection—can not only prevent but even reverse chronic diseases, including early-stage Alzheimer’s disease.

With nearly five decades of research, Dr. Ornish discusses how a whole-food, plant-based diet, moderate exercise, mindfulness practices, and social support can lead to remarkable improvements in cognition, heart disease, cancer, and even gene expression. This episode dives deep into the science behind these findings, the pushback from traditional medicine, and the potential for insurance coverage of preventive healthcare.

Join us for a conversation that challenges conventional medical thinking and offers hope and empowerment for those at risk of cognitive decline and other chronic conditions.

Key Topics Discussed:

✔️ What is Lifestyle Medicine? – How simple lifestyle changes can be more effective than high-tech, expensive treatments.
✔️ Reversing Heart Disease & Alzheimer's – The research-backed approach to stopping and even reversing disease progression.
✔️ The Science of Longevity – How lifestyle changes can lengthen telomeres and improve overall health at a cellular level.
✔️ Pushback from Traditional Medicine – Why it took decades for these ideas to gain traction in the medical community.
✔️ Medicare & Insurance Coverage – How lifestyle medicine is becoming more accessible through insurance programs.
✔️ The Role of Social Connection – Why love and support are just as crucial as diet and exercise in health and longevity.
✔️ Technology, Stress & Aging – The impact of digital overload and how mindfulness practices can counteract modern stressors.

Quotable Moments:

🗣️ "It’s not about fear of dying—it’s about the joy of living." – Dr. Dean Ornish
🗣️ "Your genes are not your fate. Lifestyle changes can turn on protective genes and turn off disease-promoting ones."
🗣️ "What’s good for your heart is good for your brain."

Resources & Links:

🔗 Learn more about Dr. Ornish’s work: Ornish.com
🔗 Research & Studies: Preventive Medicine Research Institute (PMRI)
🔗 Dr. Ornish’s Book: Undo It! (co-authored with Anne Ornish)

📢 Stay Connected:

🔔 Subscribe for more episodes of Research Renaissance
🌐 Visit: TofflerTrust.org
📩 Got thoughts or questions? Reach out to the Karen Toffler Charitable Trust

🎧 Listen Now & Discover How Lifestyle Medicine is Changing the Future of Health!

To learn more about the breakthroughs discussed in this episode and to support ongoing research, visit our website at tofflertrust.org.

Technical Podcast Support by Jon Keur at Wayfare Recording Co.

In this episode of Research Renaissance, host Deborah Westphal speaks with Katie Pizzone, Senior Director of Philanthropy at the Alzheimer’s Drug Discovery Foundation (ADDF). They discuss the critical role of philanthropy in advancing Alzheimer's research, the groundbreaking venture philanthropy model that ADDF employs, and the innovative treatments and diagnostics shaping the future of Alzheimer’s care.

Katie shares her personal journey into philanthropy, her early experiences in healthcare fundraising, and how ADDF is working to accelerate translational science—bringing new diagnostics, treatments, and preventive solutions from research to real-world impact.

Join us for a thought-provoking conversation about the intersection of philanthropy and science, the growing field of precision medicine, and how collaboration is key to curing Alzheimer’s.

Key Topics Discussed:

✔️ The Power of Venture Philanthropy – How ADDF’s unique funding model bridges the gap between early research and real-world treatments.
✔️ From Research to Patient Impact – The challenges and breakthroughs in getting Alzheimer’s treatments to market.
✔️ New Frontiers in Alzheimer’s Science – The role of repurposed drugs, biomarkers, and combination therapies in future treatments.
✔️ The Importance of Early Diagnosis – Why diagnostics are critical for prevention and personalized medicine.
✔️ Diversity in Clinical Trials – Addressing the disparities in Alzheimer’s research and treatment development.
✔️ The Role of Relationships in Philanthropy – Why trust, collaboration, and long-term partnerships drive innovation.
✔️ The Future of Neurological Research – How AI, imaging, and other technological advancements are accelerating breakthroughs.

Quotable Moments:

🗣️ "100% of every donation goes directly to science, thanks to a transformative gift from the Lauder family." – Katie Pizzone
🗣️ "Philanthropy isn’t just about funding—it’s about relationships, trust, and championing the mission together."
🗣️ "The future of Alzheimer’s treatment is precision medicine, combination therapies, and prevention—just like in cancer."

Resources & Links:

🔗 Learn more about Alzheimer’s Drug Discovery Foundation: ALZdiscovery.org
📩 Contact Katie Pizzone: kpizzone@alzdiscovery.org
📚 Explore the latest in Alzheimer’s research funding and opportunities.

📢 Stay Connected:
🔔 Subscribe for more episodes of Research Renaissance
🌐 Visit: TofflerTrust.org
📩 Join the conversation and explore funding opportunities in brain science research!

🎧 Listen Now & Discover How Philanthropy is Driving Breakthroughs in Alzheimer’s Treatment!

To learn more about the breakthroughs discussed in this episode and to support ongoing research, visit our website at tofflertrust.org.

Technical Podcast Support by Jon Keur at Wayfare Recording Co.

In this episode of Research Renaissance, host Deborah Westphal sits down with Dr. Tamar Gefen, an Associate Professor at the Mesulam Center for Cognitive Neurology and Alzheimer’s Disease at Northwestern University. Dr. Gefen, a 2023 Toffler Scholar, shares insights into her groundbreaking work on dementia syndromes and age-related cognitive disorders, including her fascinating research on cognitive "super agers."

Key Discussion Points:

• Dr. Gefen’s personal journey to becoming a clinical neuropsychologist and her passion for studying the human brain.
• What it means to be a neuropsychologist and how it combines the study of brain structure with behavior and function.
• An exploration of cognitive super agers: individuals over 80 whose memory functions as if they were decades younger.
• The significance of brain donation in Dr. Gefen’s research, as well as the emotional and spiritual connection she feels to the work.
• Insights into her research lab’s ongoing studies and how it’s contributing to the field of neurology and cognitive health.
• The importance of identifying modifiable risk factors for dementia, and how individuals can reduce their risk by focusing on heart and brain health.

Key Quotes:

"I feel like I’m among tiny gods lined up in a fridge... These organs were the source of life for every human that made that precious donation." – Dr. Tamar Gefen

"Aging suffers from poor marketing, and we need to show that aging can be graceful and fun." – Dr. Tamar Geffen

Thank you for joining us on this insightful journey into brain science. Be sure to subscribe to Research Renaissance for more conversations at the cutting edge of neurological research. Until next time, onward and upward!

To learn more about the breakthroughs discussed in this episode and to support ongoing research, visit our website at tofflertrust.org.

Technical Podcast Support by Jon Keur at Wayfare Recording Co.

Guests:

• Dr. Doug Robinson – Director of the Initiative for Careers in Science and Medicine, Johns Hopkins University
• Pamela Hamm – Director of the Summer Academic Research Experience (SARE)
• Eleana Parajon – Graduate Student and former SARE Scholar
• Temitope Adenaike – Current SARE Scholar
• Aiden Houser – Current SARE Scholar

Summary:
In this episode, we dive into the transformative Summer Academic Research Experience (SARE) at Johns Hopkins University, a program designed to provide high school students from underrepresented communities the opportunity to gain hands-on research experience. Dr. Doug Robinson and Pamela Hamm share the program’s vision, while current students and alumni, including Eleana, Temi and Aiden, recount their personal journeys in research and mentorship. We explore the program’s long-term impact, its unique structure, and the challenges in scaling it to reach even more young scientists.

Key Topics:

• The SARE program's unique combination of academic instruction and real-world research experience
• Stories from SARE scholars on how the program has shaped their educational and career aspirations
• The critical role of mentorship in empowering the next generation of scientists
• Insights on the long-term success of SARE, with 74% of participants graduating college within four years
• Challenges in sustaining and expanding the program, including funding and lab space limitations
• The future vision for SARE to grow beyond Johns Hopkins and expand across the country

Memorable Quotes:

• "We want to see scholars who are inspired, motivated, and fired up. This program is about giving them the opportunity to realize their full potential." – Dr. Doug Robinson
• "When students spend eight weeks feeling valued, listened to, and seen, it motivates them to go back into their schools and ask for what they need. It’s incredible to watch their growth." – Pamela Hamm
• "The SARE program made me love science even more. It gave me the confidence to know that I can pursue this as a career." – Temitope Adenaike, SARE Scholar
• “I was just really proud of the fact that now large organizations like QuestBridge are recognizing my potential, talent and ability.” - Aiden Houser, SARE Scholar
• "I hope for a more equitable health landscape. Investing in young people is the key to making that a reality." – Eleana Parajon, SARE Graduate and Mentor

To learn more about the SARE program and how to support its mission, visit the Initiative for Careers in Science and Medicine (CSM) at Johns Hopkins here. For partnership opportunities or to contribute to the program, contact Dr. Doug Robinson at dnr@jhi.edu.

Applications for the 2025 SARE program open on November 1st and close on February 1st. Visit the SARE program page for details on how to apply.

Thank you for joining us on this episode of Research Renaissance. Stay tuned for more discussions with leading voices in brain science and the people shaping the future of research. Until next time—onward and upward!

To learn more about the breakthroughs discussed in this episode and to support ongoing research, visit our website at tofflertrust.org.

Technical Podcast Support by Jon Keur at Wayfare Recording Co.

In this enlightening episode of Research Renaissance, Deborah Westphal speaks with Dr. Robert Vassar, a renowned neuroscientist and Director of the Mesulam Center for Cognitive Neurology and Alzheimer's Disease at Northwestern University. Dr. Vassar shares his personal journey into the field of Alzheimer’s research, the evolution of diagnostic tools, and the latest technological breakthroughs in the fight against neurodegenerative diseases.

Key Topics Covered:

• Dr. Vassar’s Early Inspirations: Dr. Vassar shares his childhood fascination with science, the path that led him away from his dream of becoming an astronaut, and his ultimate decision to pursue biology and neuroscience.
• The Influence of Family: A deeply personal connection to Alzheimer’s, driven by his mother’s diagnosis in 1983, crystallized Dr. Vassar’s purpose and career focus on researching this devastating disease.
• Advances in Alzheimer’s Diagnosis: Dr. Vassar details how the process of diagnosing Alzheimer’s has transformed from rudimentary memory tests in the 1980s to advanced tools like positron emission tomography (PET) scans and emerging blood biomarker technologies.
• The Role of Transgenic Mice in Alzheimer’s Research: Dr. Vassar explains the development of Alzheimer’s disease transgenic mice and their critical role in understanding the disease’s pathology and developing new treatments.
• Mentorship and Scientific Thinking: Insights from his postdoctoral experience with Nobel Laureate Richard Axel taught Dr. Vassar methodical scientific thinking, a key lesson he now passes on to his mentees.
• Exciting New Therapies on the Horizon: The potential of anti-tau therapies, antisense oligonucleotides (ASOs), and microglial cell research as promising avenues in Alzheimer’s treatment are explored.
• Super-Aging Research: Dr. Vassar discusses Northwestern’s unique research on “superagers,” elderly individuals with superior cognitive function, and the factors that may contribute to their resilience against dementia.
• The Importance of Multidisciplinary Approaches: From molecular studies to societal impacts, Dr. Vassar emphasizes the value of combining pharmacological and non-pharmacological methods in understanding and treating Alzheimer’s disease.

Memorable Quotes:

"My purpose in life crystallized when my mother was diagnosed with Alzheimer's. I knew I had to study this disease to try to stop it."

"The future of Alzheimer’s treatment will rely on prevention. We need to catch the disease before symptoms even begin."

"Our study participants are the real heroes. Without their altruistic contributions, we couldn’t make any progress."

Listeners interested in supporting Alzheimer’s research or participating in studies at Northwestern can visit the Mesulam Center for Cognitive Neurology and Alzheimer's Disease website for more information. The center welcomes volunteers for clinical trials and other research initiatives.

For more updates on cutting-edge research in brain science, subscribe to Research Renaissance and visit the Karen Toffler Charitable Trust website at tofflertrust.org. Share your thoughts, suggestions, or inquiries by contacting us through the website.

To learn more about the breakthroughs discussed in this episode and to support ongoing research, visit our website at tofflertrust.org.

Technical Podcast Support by Jon Keur at Wayfare Recording Co.

 In this compelling episode of Research Renaissance, host Deborah Westphal sits down with Afreen Allam, the CEO and founder of SiNON Nano Sciences and a 2023 Termeer Fellow. Afreen shares her journey from aspiring medical student to biotech entrepreneur, discussing her groundbreaking work in drug delivery for neurological diseases. The conversation delves into the challenges and triumphs of developing a platform that can cross the blood-brain barrier, offering hope for the treatment of diseases like Cancer, Alzheimer's, Parkinson's, and brain tumors.

Key Discussion Points:

1. SiNON Nano Sciences' Mission: Afreen explains the innovative approach her company takes to target drug delivery across the blood-brain barrier, using a carbon-based nanoparticle that can safely and effectively transport medications to the brain.
2. Personal Journey: Afreen reflects on her transition from a pre-medical student to a biotech entrepreneur, sharing how her experiences volunteering at the Duke Cancer Center inspired her to pursue research that could improve the quality of life for patients.
3. Challenges in Drug Delivery: The discussion covers the unique difficulties of delivering drugs to the brain, the limitations of current technologies, and how SiNON Nano Sciences aims to overcome these obstacles with their platform.
4. The Importance of Support and Mentorship: Afreen highlights the significance of mentorship and support systems, particularly her experience as a 2023 Termeer Fellow, which provided her with valuable resources, connections, and guidance.
5. The Future of Drug Delivery: Afreen discusses the potential partnerships with pharmaceutical companies and the importance of collaboration in advancing treatments for neurological diseases.

Guest Bio: Afreen Allam is the CEO and founder of SiNON Nano Sciences, a biotech startup focused on developing a platform for targeted drug delivery to the brain. A 2023 Termeer Fellow, Afreen is passionate about improving patient outcomes and has a background in biochemistry, microbiology, and business.

Call to Action: Subscribe to Research Renaissance for more episodes featuring trailblazers in brain science and healthcare innovation. Visit tofflertrust.org for additional resources and updates. Until then, onward and upward!

To learn more about the breakthroughs discussed in this episode and to support ongoing research, visit our website at tofflertrust.org.

Technical Podcast Support by Jon Keur at Wayfare Recording Co.